Clinical trial
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
NCT00136565 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00136565 |
|---|---|
| Title | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma |
| Official title | A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Janssen-Cilag International NV Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Velcade, Doxorubicin, Prednisone, Cyclophosphamide, Vindesine, Bleomycin |
| Enrollment | 60 |
| Start date | Jan 8, 2006 |
| Primary completion | Apr 18, 2011 |
| Completion | Apr 18, 2011 |
| First posted | Aug 29, 2005 |
| Last update posted | Aug 23, 2018 |
| Countries | Belgium, France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: